The use of ace inhibitors influences the risk of progression of BD-IPMNs under follow-up.
Valente R, Crippa S, Arnelo U, Vanella G, Zerboni G, Zarantonello L, Fogliati A, Arcidiacono PG, Vujasinovic M, Lohr JM, Falconi M, Capurso G, Del Chiaro M.
Valente R, et al. Among authors: arnelo u.
Pancreatology. 2022 May;22(4):516-524. doi: 10.1016/j.pan.2022.03.020. Epub 2022 Mar 31.
Pancreatology. 2022.
PMID: 35431111